CLINICAL TRIAL ASSAY BASED ON
FOUNDATIONONE® CDx

Expand Your Clinical Trial Population with **Our HRD Signature** (HRDsig)

HRDsig can identify more patients, including those **with or without relevant HRR gene mutations**, that may respond to therapy.

2023 PUBLICATION IN OVARIAN CANCER[1]

39% of patients were **HRDsig+** compared to **18% of patients** who were ***BRCA1/2+***.

Mutation+ Wild-Type with BRCAness

HRDsig has **validation across tumor types** that can support **clinical trials** and future **CDx development** for tumor-specific or pan-tumor applications.

Ovarian	Prostate	Breast	Pancreas	Lung

SEE DATA EXAMPLES ON BACK

6% Prevalence of HRDsig+ in a pan-tumor setting.[2]

HRDsig identified 18% more HRD positive results than Myriad GIS in an ovarian cancer study using abstracted results from the Flatiron Health-Foundation Medicine CGDB (n=156).[3]



93% overall percent **agreement with Myriad GIS** for tissue specimens collected within 90 days of each other.[3]

Foundation Medicine's **HRDsig biomarker** is **now available for investigational use** on the **clinical trial assay based on FoundationOne®CDx**, our tissue-based CGP test.[4]

DATA EXAMPLE: OVARIAN CANCER[1]



HRDsig+ is detected in 39% of patients overall, with 58% of these patients being BRCA1/2wt

DATA EXAMPLE: BREAST CANCER[5]



HRDsig is a comprehensive, scar-based signature with diverse potential use cases for therapy development.

1. **Better performance than gLOH** (sensitivity and specificity)[2] and designed for use **across tumor types**
2. **Captures non-genomic mechanisms** of HRD, like *BRCA1* promoter methylation
3. Detects different HRD phenotypes and **can identify monoallelic HRR passenger mutations as HRDsig-**

HRDsig was developed with the use of machine-learning methods and further explored using our FoundationCore® database, which contains comprehensive, de-identified genomic data from >600,000 patient samples.[3]

HRDsig can also be explored for research collaborations using blood or plasma samples—please contact us for more details.

HRD = Homologous Recombination Deficiency. HRR = Homologous Recombination Repair. gLOH = Genomic Loss of Heterozygosity

References:

1. Richardson et al. 2023;41(16_suppl):5583-5583. doi: https://doi.org/10.1200/jco.2023.41.16_suppl.5583.
2. Antonarakis E, et al. Cancer Res. 2022;82(12_supp):1249-1249.
3. Data on file, Foundation Medicine, Inc. 2022.
4. For Investigational Use Only. The performance characteristics of this product have not been established.
5. Batalini et al. 2023 JCO Precis Oncol 7:32300091. doi: https://doi.org/10.1200/PO.23.00091

FOUNDATION MEDICINE®

www.foundationmedicine.com | Tel 888.988.3639 | Fax 617.418.2290 | US-FDX-2300058 V2.0